145 related articles for article (PubMed ID: 25173477)
21. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal.
Upreti SR; Janusz KB; Schluter WW; Bichha RP; Shakya G; Biggerstaff BJ; Shrestha MM; Sedai TR; Fischer M; Gibbons RV; Shrestha SK; Hills SL
Am J Trop Med Hyg; 2013 Mar; 88(3):464-8. PubMed ID: 23358643
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
[TBL] [Abstract][Full Text] [Related]
24. Reduction patterns of Japanese encephalitis incidence following vaccine introduction into long-term expanded program on immunization in Yunnan Province, China.
Hu XT; Li QF; Ma C; Zhao ZX; He LF; Tang TT; Yu W; Owiti P
Infect Dis Poverty; 2019 Dec; 8(1):102. PubMed ID: 31818328
[TBL] [Abstract][Full Text] [Related]
25. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.
Li X; Ma SJ; Liu X; Jiang LN; Zhou JH; Xiong YQ; Ding H; Chen Q
Hum Vaccin Immunother; 2014; 10(12):3579-93. PubMed ID: 25668666
[TBL] [Abstract][Full Text] [Related]
27. Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal.
Upreti SR; Lindsey NP; Bohara R; Choudhary GR; Shakya S; Gautam M; Giri JN; Fischer M; Hills SL
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005866. PubMed ID: 28934197
[TBL] [Abstract][Full Text] [Related]
28. Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia.
Islam N; Lau C; Leeb A; Mills D; Furuya-Kanamori L
Hum Vaccin Immunother; 2022 Dec; 18(1):2020573. PubMed ID: 35254947
[TBL] [Abstract][Full Text] [Related]
29. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
[TBL] [Abstract][Full Text] [Related]
30. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults.
Khan SA; Kakati S; Dutta P; Chowdhury P; Borah J; Topno R; Jadhav SM; Mohapatra PK; Mahanta J; Gupte MD
Indian J Med Res; 2016 Dec; 144(6):886-892. PubMed ID: 28474625
[TBL] [Abstract][Full Text] [Related]
32. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
[No Abstract] [Full Text] [Related]
33. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
34. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.
Nakayama T; Onoda K
Vaccine; 2007 Jan; 25(3):570-6. PubMed ID: 16945455
[TBL] [Abstract][Full Text] [Related]
35. Adverse events following immunisation with SA 14-14-2 Japanese encephalitis vaccine in children of Kolar in Karnataka.
Ranganath BG; Hiremath SG
J Indian Med Assoc; 2012 Jan; 110(1):10-2. PubMed ID: 23029822
[TBL] [Abstract][Full Text] [Related]
36. Japanese encephalitis vaccine: need of the hour in endemic states of India.
Verma R
Hum Vaccin Immunother; 2012 Apr; 8(4):491-3. PubMed ID: 22370517
[TBL] [Abstract][Full Text] [Related]
37. Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.
Chen F; Pan X; Liang H; Shen L; Wang Y; Chen Y; Lv H; Hu Y
Hum Vaccin Immunother; 2022 Dec; 18(7):2152256. PubMed ID: 36484114
[TBL] [Abstract][Full Text] [Related]
38. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka.
Sanchayan K; Fernandopulle R; Amarasinghe A; Thiyahiny SN; Sri Ranganathan S
Ceylon Med J; 2016 Sept; 61(3):99-105. PubMed ID: 27727408
[TBL] [Abstract][Full Text] [Related]
39. Adverse events following immunization in Ontario's female school-based HPV program.
Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
[TBL] [Abstract][Full Text] [Related]
40. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
